New emerging drugs in soft tissue sarcoma
- 31 July 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 59 (1) , 74-84
- https://doi.org/10.1016/j.critrevonc.2005.12.002
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Metastatic Soft Tissue Sarcoma in AdultsAmerican Journal of Cancer, 2003
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomaEuropean Journal Of Cancer, 2001
- Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupJournal of Clinical Oncology, 2000
- High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupBritish Journal of Cancer, 1998
- Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With SarcomasAmerican Journal of Clinical Oncology, 1998
- Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.Journal of Clinical Oncology, 1998
- A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomasCancer, 1997
- High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.Journal of Clinical Oncology, 1997
- Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.Journal of Clinical Oncology, 1997
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Journal of Clinical Oncology, 1993